- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03424733
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
August 13, 2019 updated by: Mary Ann Picone, MD, Holy Name Medical Center, Inc.
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a
Some of the most common side effects of the multiple sclerosis drug Plegridy (pegylated interferon beta-1a) include flu-like symptoms and injection site reactions.
Physicians often advise patients to take Tylenol or aspirin prior to injection, but in this study the investigators evaluated whether using a low dose of oral steroid in combination with Tylenol reduced flu-like symptoms and injection site reactions.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Multiple Sclerosis (MS) is a chronic neurological disease characterized by demyelination of the brain and spine.
Currently, there are several treatments designed to decrease the frequency of attacks and delay disease progression.
One of these treatments, interferon beta, has shown the potential to decrease relapse rates by approximately 30%, but because the body quickly clears these proteins, patients require more frequent dosing.
Another interferon therapy called pegylated interferon beta-1a (Plegridy) was released and it was shown to last longer in the body than interferon beta-1a.
This is why Plegridy can be take by an injection into tissue under the skin once every 14 days.
However, some of the most common side effects of interferon beta therapy include flu-like symptoms and injection skin reactions, which can often cause patients to want to stop treatment.
Clinical practitioners often advise patients to take acetaminophen (Tylenol) or aspirin before the injection in order to prevent the onset or decrease the severity of flu-like symptoms.
A previous study with patients taking interferon beta-1a showed that taking a low dose oral steroid (prednisone) in addiction to a medication like Tylenol reduced flu-like symptoms compared to just taking Tylenol by itself.
Because Plegridy lasts longer in the body and has more convenient dosing for patients, researchers in this study decided to investigate whether taking prednisone in addition to acetaminophen before the injection would help decrease or prevent the occurrence of flu-like symptoms and injection site reactions in patients taking the therapy.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mary Ann Picone, MD
- Phone Number: 201-837-0727
- Email: M-picone@mail.holyname.org
Study Locations
-
-
New Jersey
-
Teaneck, New Jersey, United States, 07666
- Recruiting
- Holy Name Medical Center
-
Contact:
- Mary Ann Picone, MD
- Phone Number: 201-837-0727
- Email: M-picone@mail.holyname.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- diagnosed any form of MS (relapsing remitting, primary progressive, secondary progressive), any EDSS (expanded stability status scale) score
Exclusion Criteria:
- prior allergic reaction to interferon products, congestive heart failure, elevated liver enzymes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Current Plegridy Users
Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks.
These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration.
Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
|
Self injection into area of high adipose content.
Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
Other Names:
Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Other Names:
|
Experimental: New Plegridy Users
Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose.
Titrations, along with full dose injections (125 micrograms) occur every two weeks.
Patients must take two 325mg tablets of Tylenol prior to each titration injection.
The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection.
The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
|
Self injection into area of high adipose content.
Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
Other Names:
Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Flu-like symptoms
Time Frame: 12 to 16 weeks
|
Reduced flu-like symptoms from Plegridy injections due to taking both Tylenol and Prednisone prior to treatment.
Flu-like symptoms are measured every 6 hours for 48 hours after injection by patients self reporting their muscle aches, temperature, chills, and fatigue on a Holy Name administered Flu-like symptom questionnaire.
|
12 to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Injection site reactions
Time Frame: 12 to 16 weeks
|
Reduced injection site reactions from Plegridy injections due to taking both Tylenol and Prednisone prior to injection.
Injection site reactions are reported to a clinical research assistant approximately one week after injection.
If present, patients must record their injection site reactions using a Holy Name administered tape measurer in centimeters, as well as descriptive characteristics of the injection (location on body, swelling, redness, itching, and pain).
The clinical research assistant records all of the data on an injection site reaction form.
|
12 to 16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Rio J, Nos C, Marzo ME, Tintore M, Montalban X. Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS. Neurology. 1998 Jun;50(6):1910-2. doi: 10.1212/wnl.50.6.1910.
- Brandes DW, Bigley K, Hornstein W, Cohen H, Au W, Shubin R. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. Curr Med Res Opin. 2007 Jul;23(7):1667-72. doi: 10.1185/030079907x210741.
- Rio J, Nos C, Bonaventura I, Arroyo R, Genis D, Sureda B, Ara JR, Brieva L, Martin J, Saiz A, Sanchez Lopez F, Prieto JM, Roquer J, Dorado JF, Montalban X. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology. 2004 Aug 10;63(3):525-8. doi: 10.1212/01.wnl.0000133206.44931.25.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2017
Primary Completion (Anticipated)
May 1, 2020
Study Completion (Anticipated)
May 31, 2020
Study Registration Dates
First Submitted
January 31, 2018
First Submitted That Met QC Criteria
February 5, 2018
First Posted (Actual)
February 7, 2018
Study Record Updates
Last Update Posted (Actual)
August 15, 2019
Last Update Submitted That Met QC Criteria
August 13, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antipyretics
- Antineoplastic Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Adjuvants, Immunologic
- Interferons
- Interferon beta-1a
- Acetaminophen
- Prednisone
- Interferon-beta
Other Study ID Numbers
- US-PEG-16-10990
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Plegridy
-
BiogenCompleted
-
Pontificia Universidad Catolica de ChileTelethon Kids InstituteCompletedCovid19 | SARS-CoV Infection | InterferonChile
-
BiogenCompleted
-
BiogenCompletedMultiple Sclerosis | Exposure During PregnancySpain, Italy, Australia, Poland, United Kingdom, United States, Canada, France, Germany, Ireland
-
BiogenTerminatedMultiple Sclerosis, Relapsing-RemittingMexico, Turkey, United States, Hungary, Taiwan, Thailand, Korea, Republic of, Saudi Arabia, Malaysia, Colombia, Estonia, Jordan, Tunisia
-
BiogenRecruitingMultiple Sclerosis, Relapsing-RemittingSpain, Germany, Croatia, Turkey, Saudi Arabia, Hungary, Belgium, Australia, France, Portugal, Slovakia, United States, Bulgaria, Greece, Kuwait, Russian Federation, Tunisia, Italy, Argentina, Czechia, Israel, Serbia
-
BiogenCompletedRelapsing-Remitting Multiple Sclerosis (RRMS)Italy
-
BiogenCompletedRelapsing Forms of Multiple SclerosisUnited States, Italy, Switzerland, Canada, Australia, Germany, Spain, France, Portugal, Netherlands, United Kingdom, Denmark, Austria, Ireland
-
BiogenCompletedRelapsing Multiple SclerosisUnited States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
-
BiogenCompletedRelapsing Remitting Multiple SclerosisPortugal